Cantargia and Glycotope Biotechnology have announced an agreement on the production of Cantargia's proprietary monoclonal antibody CAN04. The product candidate CAN04 is directed against the target molecule IL1RAP, expressed on cancer stem cells, as well on mature cancer cells. Through the agreement, Glycotope Biotechnology will be Cantargia's production partner to obtain material for the clinical studies of CAN04 in cancer patients.
Glycotope Biotechnology will be responsible for the development and the GMP (Good Manufacturing Practices) production of CAN04. Glycotope Biotechnology will manufacture the material to be used in both future toxicology studies and clinical trials.
"The collaboration with Glycotope Biotechnology will be a cornerstone in the development of CAN04. We look forward to work with Glycotope Biotechnology", says Göran Forsberg, CEO of Cantargia.
"To bring Cantargia's lead drug candidate into clinical trials will be a great opportunity for Glycotope Biotechnology as Contract Manufacturer for innovative biopharmaceuticals", says Franzpeter Bracht, COO of Glycotope Biotechnology.
